ClinicalTrials.gg
CompletedNCT02514473Updated Oct 23, 2017Results posted

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

A Phase 3 interventional study of VX-809 and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 54 sites in 9 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-10-23.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.

Enrollment
6th of 20
206 · median 66
Started
2015
with 2 others
Phase 3
10 of 20
none open now
Registered
13th of 20
by date
Lead sponsor
20 of 20
Vertex Pharmaceuticals Incorporated

Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 6th largest by enrollment, is one of 3 that started in 2015, is one of 10 in phase 3, and was the 13th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →

About lumacaftor

lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing lumacaftor in Cystic Fibrosis as a file.
02

Study summary

To evaluate the efficacy and safety of lumacaftor in combination with ivacaftor in subjects aged 6 Through 11 years with cystic fibrosis (CF), homozygous for the F508del CF transmembrane conductance regulator (CFTR) mutation

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who weigh ≥15 kg without shoes a the Screening Visit
  • Subjects with confirmed diagnosis of CF at the Screening Visit.
  • Subjects who are homozygous for the F508del CFTR mutation
  • Subjects with ppFEV1 of ≥70 percentage points adjusted for age, sex, and height
  • Subjects with a screening LCI2.5 result greater than or equal to 7.5

Exclusion criteria

Exclusion Criteria:

  • History of any comorbidity reviewed at the Screening Visit that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.
  • Any laboratory abnormalities at the Screening Visit that would interfere with the study assessments or pose an undue risk for the subject
  • Clinically significant abnormalities in , liver function, or renal function at the Screening Visit.
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 28 days before Day 1
  • History of solid organ or hematological transplantation at the Screening Visit
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
206 participants (actual)

Study arms

  • Experimental
    LUM/IVA

    Fixed-dose combination with lumacaftor (LUM) 200 mg every 12 hours (q12h)/ ivacaftor (IVA) 250 mg q12h

    Drug: VX-809 · Drug: VX-770

  • Placebo comparator
    Placebo

    Matching placebo q12h

    Drug: Placebo

Interventions

  • DrugVX-809

    Also known as: lumacaftor

  • DrugPlacebo
  • DrugVX-770

    Also known as: ivacaftor

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Lung Clearance Index 2.5 (LCI2.5) Through Week 24

    Lung clearance index (LCI) is a measure of ventilation inhomogeneity that is derived from a multiple breath washout test using Nitrogen (N2). LCI2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.

    Time frame: Baseline, Through Week 24

Secondary outcomes

  1. Average Absolute Change From Baseline in Sweat Chloride at Day 15 and Week 4

    Sweat samples were collected using an approved collection device. Baseline was defined as the average of the measurements at screening and on Day 1 pre-dose. Change from Baseline in sweat chloride at Day 15 and Week 4 was calculated. The average of the 2 values (Change at Day 15 and Week 4) was reported.

    Time frame: Baseline, Day 15 and Week 4

  2. Absolute Change From Baseline in Body Mass Index (BMI) at Week 24

    BMI was defined as weight in kg divided by height in square meter (m\^2).

    Time frame: Baseline, Week 24

  3. Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 24

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: Baseline, Through Week 24

  4. Absolute Change From Baseline in Lung Clearance Index 5.0 (LCI5.0) Through Week 24

    LCI is a measure of ventilation inhomogeneity that is derived from a multiple breath washout test using Nitrogen (N2). LCI5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.

    Time frame: Baseline, Through Week 24

  5. Absolute Change From Baseline in Sweat Chloride at Week 24

    Sweat samples were collected using an approved collection device.

    Time frame: Baseline, Week 24

  6. Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Wang standards were used to calculate ppFEV1 (for age, gender, race, and height).

    Time frame: Baseline, Through Week 24

  7. Relative Change From Baseline in ppFEV1 Through Week 24

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Wang standards were used to calculate ppFEV1 (for age, gender, race, and height).

    Time frame: Baseline, Through Week 24

  8. Absolute Change From Baseline in BMI-for-age Z-score at Week 24

    BMI was defined as weight in kg divided by height in m\^2. z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score (BMI z-score). The BMI-for-age z-scores were calculated using National Center for Health Statistics growth charts.

    Time frame: Baseline, Week 24

  9. Absolute Change From Baseline in Weight at Week 24

    Time frame: Baseline, Week 24

  10. Absolute Change From Baseline in Weight-for-age Z-score at Week 24

    Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score (weight z-score). The weight-for-age z-scores were calculated using National Center for Health Statistics growth charts.

    Time frame: Baseline, Week 24

  11. Absolute Change From Baseline in Height at Week 24

    Time frame: Baseline, Week 24

  12. Absolute Change From Baseline in Height-for-age Z-score at Week 24

    Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard. Height, adjusted for age and sex, was analyzed as height-for-age z-score (height z-score). The height-for-age z-scores were calculated using National Center for Health Statistics growth charts.

    Time frame: Baseline, Week 24

  13. Absolute Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Domains Through Week 24

    The TSQM is a 14-item self-administered questionnaire which measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed to a scale from 0 to 100, where higher scores indicate greater satisfaction.

    Time frame: Baseline, Through Week 24

  14. Number of Pulmonary Exacerbation Events

    Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. The number of events were reported.

    Time frame: Baseline through Week 24

  15. Percentage of Participants With At Least 1 Pulmonary Exacerbation Event

    Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

    Time frame: Baseline through Week 24

  16. Time-to-first Pulmonary Exacerbation

    Time-to-first pulmonary exacerbation was analyzed using the Kaplan-Meier estimates. Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

    Time frame: Baseline through Week 24

  17. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug to Week 28 was considered treatment-emergent.

    Time frame: Baseline up to Week 28

  18. Average Pre-dose Concentration (Ctrough,Ave) and Average 3 to 6 Hours Post-dose Concentration (C3-6h,Ave) For Lumacaftor and Ivacaftor

    Ctrough,ave is average of individual pre-dose observed concentrations across Week 4 and 24. C3-6h,ave is average of individual 3 to 6 hours post-dose observed concentrations across Day 1, 15 and Week 4. This outcome was not planned to be assessed in Placebo arm.

    Time frame: For Ctrough,ave: before morning dose on Week 4 and 24; For C3-6h,ave: 3 to 6 hours after morning dose on Day 1, 15 and Week 4

07

Results

Posted Oct 23, 2017

Participant flow

Participant flow — Overall Study
MilestonePlaceboLUM/IVA
Started101103
Completed9898
Not completed35
Withdrew: Adverse event02
Withdrew: Withdrawal by subject21
Withdrew: Lost to follow-up01
Withdrew: Other11

Outcome measures

PrimaryAbsolute Change From Baseline in Lung Clearance Index 2.5 (LCI2.5) Through Week 24

Lung clearance index (LCI) is a measure of ventilation inhomogeneity that is derived from a multiple breath washout test using Nitrogen (N2). LCI2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.

Time frame:
Baseline, Through Week 24
Reported as:
Least squares mean · Ratio
Absolute Change From Baseline in Lung Clearance Index 2.5 (LCI2.5) Through Week 24
RatioPlaceboLUM/IVA
Absolute Change From Baseline in Lung Clearance Index 2.5 (LCI2.5) Through Week 240.08 ± 0.13-1.01 ± 0.13
Statistical analysis
  • Placebo vs LUM/IVA · MMRM · p = < 0.0001 · Least square (ls) mean difference: -1.09 · 95% CI -1.43 to -0.75
SecondaryAverage Absolute Change From Baseline in Sweat Chloride at Day 15 and Week 4

Sweat samples were collected using an approved collection device. Baseline was defined as the average of the measurements at screening and on Day 1 pre-dose. Change from Baseline in sweat chloride at Day 15 and Week 4 was calculated. The average of the 2 values (Change at Day 15 and Week 4) was reported.

Time frame:
Baseline, Day 15 and Week 4
Reported as:
Least squares mean · Millimole per liter (mmol/L)
Average Absolute Change From Baseline in Sweat Chloride at Day 15 and Week 4
Millimole per liter (mmol/L)PlaceboLUM/IVA
Average Absolute Change From Baseline in Sweat Chloride at Day 15 and Week 40.8 ± 1.0-20.0 ± 1.0
SecondaryAbsolute Change From Baseline in Body Mass Index (BMI) at Week 24

BMI was defined as weight in kg divided by height in square meter (m\^2).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Kg/m^2
Absolute Change From Baseline in Body Mass Index (BMI) at Week 24
Kg/m^2PlaceboLUM/IVA
Absolute Change From Baseline in Body Mass Index (BMI) at Week 240.27 ± 0.070.38 ± 0.07
SecondaryAbsolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 24

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
Baseline, Through Week 24
Reported as:
Least squares mean · Units on a scale
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 24
Units on a scalePlaceboLUM/IVA
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 243.0 ± 1.05.5 ± 1.0
SecondaryAbsolute Change From Baseline in Lung Clearance Index 5.0 (LCI5.0) Through Week 24

LCI is a measure of ventilation inhomogeneity that is derived from a multiple breath washout test using Nitrogen (N2). LCI5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.

Time frame:
Baseline, Through Week 24
Reported as:
Least squares mean · Ratio
Absolute Change From Baseline in Lung Clearance Index 5.0 (LCI5.0) Through Week 24
RatioPlaceboLUM/IVA
Absolute Change From Baseline in Lung Clearance Index 5.0 (LCI5.0) Through Week 240.08 ± 0.05-0.36 ± 0.05
SecondaryAbsolute Change From Baseline in Sweat Chloride at Week 24

Sweat samples were collected using an approved collection device.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mmol/L
Absolute Change From Baseline in Sweat Chloride at Week 24
mmol/LPlaceboLUM/IVA
Absolute Change From Baseline in Sweat Chloride at Week 243.2 ± 1.3-21.6 ± 1.3
SecondaryAbsolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Wang standards were used to calculate ppFEV1 (for age, gender, race, and height).

Time frame:
Baseline, Through Week 24
Reported as:
Least squares mean · Percent predicted of FEV1
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24
Percent predicted of FEV1PlaceboLUM/IVA
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24-1.3 ± 0.81.1 ± 0.8
SecondaryRelative Change From Baseline in ppFEV1 Through Week 24

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Wang standards were used to calculate ppFEV1 (for age, gender, race, and height).

Time frame:
Baseline, Through Week 24
Reported as:
Least squares mean · Percent change
Relative Change From Baseline in ppFEV1 Through Week 24
Percent changePlaceboLUM/IVA
Relative Change From Baseline in ppFEV1 Through Week 24-0.9 ± 1.02.2 ± 1.0
SecondaryAbsolute Change From Baseline in BMI-for-age Z-score at Week 24

BMI was defined as weight in kg divided by height in m\^2. z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score (BMI z-score). The BMI-for-age z-scores were calculated using National Center for Health Statistics growth charts.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Z-score
Absolute Change From Baseline in BMI-for-age Z-score at Week 24
Z-scorePlaceboLUM/IVA
Absolute Change From Baseline in BMI-for-age Z-score at Week 240.05 ± 0.040.08 ± 0.04
SecondaryAbsolute Change From Baseline in Weight at Week 24
Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Kg
Absolute Change From Baseline in Weight at Week 24
KgPlaceboLUM/IVA
Absolute Change From Baseline in Weight at Week 241.7 ± 0.22.0 ± 0.1
SecondaryAbsolute Change From Baseline in Weight-for-age Z-score at Week 24

Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score (weight z-score). The weight-for-age z-scores were calculated using National Center for Health Statistics growth charts.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Z-score
Absolute Change From Baseline in Weight-for-age Z-score at Week 24
Z-scorePlaceboLUM/IVA
Absolute Change From Baseline in Weight-for-age Z-score at Week 240.02 ± 0.020.06 ± 0.02
SecondaryAbsolute Change From Baseline in Height at Week 24
Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Centimeter (cm)
Absolute Change From Baseline in Height at Week 24
Centimeter (cm)PlaceboLUM/IVA
Absolute Change From Baseline in Height at Week 242.6 ± 0.12.9 ± 0.1
SecondaryAbsolute Change From Baseline in Height-for-age Z-score at Week 24

Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard. Height, adjusted for age and sex, was analyzed as height-for-age z-score (height z-score). The height-for-age z-scores were calculated using National Center for Health Statistics growth charts.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Z-score
Absolute Change From Baseline in Height-for-age Z-score at Week 24
Z-scorePlaceboLUM/IVA
Absolute Change From Baseline in Height-for-age Z-score at Week 240.00 ± 0.020.03 ± 0.02
SecondaryAbsolute Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Domains Through Week 24

The TSQM is a 14-item self-administered questionnaire which measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed to a scale from 0 to 100, where higher scores indicate greater satisfaction.

Time frame:
Baseline, Through Week 24
Reported as:
Least squares mean · Units on a scale
Absolute Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Domains Through Week 24
Units on a scalePlaceboLUM/IVA
Change Through Week 24: Effectiveness0.6 ± 1.51.7 ± 1.5
Change Through Week 24: Side Effects0.4 ± 0.8-1.0 ± 0.8
Change Through Week 24: Convenience9.9 ± 1.211.9 ± 1.2
Change Through Week 24: Global Score-2.3 ± 1.6-1.4 ± 1.6
SecondaryNumber of Pulmonary Exacerbation Events

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. The number of events were reported.

Time frame:
Baseline through Week 24
Reported as:
Number · Pulmonary exacerbation events
Number of Pulmonary Exacerbation Events
Pulmonary exacerbation eventsPlaceboLUM/IVA
Number of Pulmonary Exacerbation Events1824
SecondaryPercentage of Participants With At Least 1 Pulmonary Exacerbation Event

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

Time frame:
Baseline through Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With At Least 1 Pulmonary Exacerbation Event
Percentage of participantsPlaceboLUM/IVA
Percentage of Participants With At Least 1 Pulmonary Exacerbation Event14.919.4
SecondaryTime-to-first Pulmonary Exacerbation

Time-to-first pulmonary exacerbation was analyzed using the Kaplan-Meier estimates. Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

Time frame:
Baseline through Week 24
Reported as:
Median · Days
Time-to-first Pulmonary Exacerbation
DaysPlaceboLUM/IVA
Time-to-first Pulmonary ExacerbationNA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug to Week 28 was considered treatment-emergent.

Time frame:
Baseline up to Week 28
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsPlaceboLUM/IVA
Participants With Any Treatment-Emergent AEs9898
Participants With Treatment-Emergent SAEs1113
SecondaryAverage Pre-dose Concentration (Ctrough,Ave) and Average 3 to 6 Hours Post-dose Concentration (C3-6h,Ave) For Lumacaftor and Ivacaftor

Ctrough,ave is average of individual pre-dose observed concentrations across Week 4 and 24. C3-6h,ave is average of individual 3 to 6 hours post-dose observed concentrations across Day 1, 15 and Week 4. This outcome was not planned to be assessed in Placebo arm.

Time frame:
For Ctrough,ave: before morning dose on Week 4 and 24; For C3-6h,ave: 3 to 6 hours after morning dose on Day 1, 15 and Week 4
Reported as:
Mean · Nanogram per milliliter (ng/mL)
Average Pre-dose Concentration (Ctrough,Ave) and Average 3 to 6 Hours Post-dose Concentration (C3-6h,Ave) For Lumacaftor and Ivacaftor
Nanogram per milliliter (ng/mL)LUM/IVA
LUM: Ctrough,ave10200 ± 4460
LUM: C3-6h,ave20600 ± 6560
IVA: Ctrough,ave107 ± 91.2
IVA: C3-6h,ave821 ± 348

Adverse events

Collected over Baseline up to Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/101 (0%)11/101 (10.9%)98/101 (97%)
LUM/IVA0/103 (0%)13/103 (12.6%)98/103 (95.1%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPlaceboLUM/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations5/1018/103
Distal intestinal obstruction syndromeGastrointestinal disorders2/1010/103
Alanine aminotransferase increasedInvestigations1/1010/103
Aspartate aminotransferase increasedInvestigations1/1010/103
Transaminases increasedInvestigations1/1010/103
LymphadenitisBlood and lymphatic system disorders1/1010/103
Device related thrombosisGeneral disorders1/1010/103
ConstipationGastrointestinal disorders1/1010/103
PneumoniaInfections and infestations1/1011/103
Poor venous accessVascular disorders0/1011/103
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPlaceboLUM/IVA
CoughRespiratory, thoracic and mediastinal disorders47/10146/103
PyrexiaGeneral disorders20/10115/103
Productive coughRespiratory, thoracic and mediastinal disorders6/10118/103
Nasal congestionRespiratory, thoracic and mediastinal disorders8/10117/103
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations16/10113/103
Oropharyngeal painRespiratory, thoracic and mediastinal disorders10/10115/103
HeadacheNervous system disorders9/10113/103
Abdominal pain upperGastrointestinal disorders7/10113/103
Upper respiratory tract infectionInfections and infestations10/10113/103
FatigueGeneral disorders11/1019/103

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboLUM/IVATotal
Mean8.9 ± 1.598.7 ± 1.68.8 ± 1.59
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLUM/IVATotal
Female5863121
Male434083
08

Study locations

54 sites
  • Birmingham, Alabama, United States
  • Los Angeles, California, United States
  • Palo Alto, California, United States
  • Aurora, Colorado, United States
  • Wilmington, Delaware, United States
  • Orlando, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Iowa City, Iowa, United States
  • Boston, Massachusetts, United States
  • Minneapolis, Minnesota, United States
  • Kansas City, Missouri, United States
  • Omaha, Nebraska, United States
  • Manchester, New Hampshire, United States
  • Chapel Hill, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Dayton, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Salt Lake City, Utah, United States
  • Colchester, Vermont, United States
  • Charlottesville, Virginia, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
  • Madison, Wisconsin, United States
  • Milwaukee, Wisconsin, United States
  • Herston, Australia
  • New South Wales, Australia
  • Parkville, Australia
  • Subiaco, Australia
  • Westmead, Australia
  • Brussels, Belgium
  • Leuven, Belgium
  • Vancouver, British Columbia, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • Copenhagen, Denmark
  • Bordeaux, France
  • Bron, France
  • Paris Cedex 15, France
  • Paris, France
  • Berlin, Germany
  • Giessen, Germany
  • Hannover, Germany
  • Koeln, Germany
  • Munich, Germany
  • Stockholm, Sweden
  • Edinburgh, Lothian Region, United Kingdom
  • Leeds, West Yorkshire, United Kingdom
  • Belfast, United Kingdom
  • London, United Kingdom
09

References and documents

Publications

  • Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. PubMed 33331662 ↗
  • Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC; VX14-809-109 investigator group. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2017 Jul;5(7):557-567. doi: 10.1016/S2213-2600(17)30215-1. Epub 2017 Jun 9. Erratum In: Lancet Respir Med. 2017 Aug;5(8):e28. doi: 10.1016/S2213-2600(17)30270-9. PubMed 28606620 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2015
First posted
Aug 3, 2015
Start
Jul 2015
Primary completionActual
Sep 2016
CompletionActual
Sep 2016
Results first posted
Oct 23, 2017
Last update
Oct 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02514473
Responsible party
Sponsor
First posted
Aug 3, 2015
Start date
Jul 2015
Primary completion
Sep 2016
Completion
Sep 2016
Results posted
Oct 23, 2017
Last update
Oct 23, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lumacaftor · Ivacaftor

Start the discussion